
Oculis lists at Nasdaq through SPAC merger
Upon closing of the $104m SPAC deal with European Biotech Acquisition Corp, Oculis had a pro-forma enterprise value of approximately $220m and a cash...

First hints for leukopenia diagnostic in MS
Disease-modifying therapies for multiple sclerosis (MS) may positively influence the composition of the intestinal flora. At least this is what a...

ExeVir receives EIB risk finance for multiple COVID-19 nanobody
With the resurgence of COVID-19 in China, ExeVir BIO sees commercial potential in the future treatment of immunocompromised people, who make up 3%...

First allogeneic cancer immunotherapy hits market
On December 20th, the European Commission approved Tabelecleucel (EbvalloTM) as a monotherapy for the treatment of adult and paediatric patients who...

Neurodegenerative disorders are being fought with €28m
The Danish biotech Teitur Trophics ApS, aiming to treat chronic neurological disorders, has completed a €28m Series A funding. With the money, Teitur...

Paleo raised € 12 m in Series A financing round
The financing round was led by DSM Venturing, Planet A Ventures along with Gimv, SFPIM Relaunch, Beyond Impact, and Siddhi Capital. The proceeds will...

Evidence of deliberate climate damage
For decades, some members of the fossil fuel industry tried to convince the public that a causative link between fossil fuel use and climate warming...